Femasys Inc. received written notice from Nasdaq regarding its regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company regained compliance following a 1-for-20 reverse stock split effective June 5, 2026, which brought the closing bid price above $1.00 per share. Femasys Inc. operates in the medical technology industry and develops surgical-robotic and surgical-robotic-assisted technology solutions.